Le Lézard
Classified in: Health
Subject: TRI

Drug Tests That Could Halt Runaway Increase in Opioid Overdoses Highlighted in January Issue of AACC's The Journal of Applied Laboratory Medicine



WASHINGTON, Jan. 2, 2018 /PRNewswire-USNewswire/ -- A special issue of AACC's The Journal of Applied Laboratory Medicine, "Laboratory Support of Pain Management," features groundbreaking new drug tests that could reverse the staggering climb of prescription drug overdoses in the U.S.

Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

For the first time since the early 1960s, U.S. life expectancy has dropped for a second year in a row, a decline driven by a 21% rise in drug overdose deaths. Prescription and illicit opioids continue to cause the lion's share of these deaths, but benzodiazepine overdoses have also soared in recent years, with benzodiazepines accounting for the second highest number of prescription drug deaths after opioids in 2013. In spite of the toll that prescription drugs are taking on the nation, however, there are many scenarios in which these drugs are still the most effective treatment for pain, such as after surgery or in the case of patients with debilitating chronic pain.

Advances in laboratory drug tests will play a crucial role in helping healthcare providers to ensure access to pain medication for patients who need it without contributing to escalating rates of addiction. This special issue of The Journal of Applied Laboratory Medicine features research on one such advancement, a new drug testing approach that vastly improves detection of illicit benzodiazepine use among chronic pain patients. The special issue also includes research that provides technical insights on the development of laboratory drug tests and the sample types used with these tests, articles that discuss important cost considerations associated with urine drug testing, and expert perspectives on the opioid era overall.

"This special issue which focuses on the laboratory support of pain management ... addresses many of the laboratory issues and challenges [in this field] and provides recommendations for clinical laboratorians, practicing pain management clinicians, policy makers, regulatory bodies, and/or health insurance companies," wrote issue editors and drug testing experts Drs. Paul Jannetto and Loralie Langman in the preamble to the special issue. "[Experts] discuss the legalities that govern many aspects of opioid prescribing and present clinical practice strategies to inform medical providers about the tools and laboratory tests used to minimize harm to patients."

For more about the findings in the special Pain Management issue, follow us on Twitter at @JALM_AACC.

About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Launched by AACC in 2016, The Journal of Applied Laboratory Medicine is an international, peer-reviewed publication that showcases the applied research in clinical laboratory science that is driving innovation forward in healthcare.

Christine DeLong
AACC
Manager, Communications & PR
(p) 202.835.8722
cdelong@aacc.org

Molly Polen
AACC
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
mpolen@aacc.org

SOURCE AACC


These press releases may also interest you

at 07:33
VitalHub Corp. (the "Company") is pleased to announce the sale of the TREAT EHR solution ("TREAT") to Stella's Place, a Toronto-based young adult mental health agency, and a Reconnect Community Health Services ("Reconnect") affiliate. TREAT, the...

at 07:30
Researched by Industrial Info Resources (Sugar Land, Texas) -- In the July 11 webinar regarding spending in the global Pharmaceutical-Biotech Industry, Annette Kreuger, Industrial Info's vice president of Pharma-Bio Industry research, and Shaheen...

at 07:30
ProMIS Neurosciences, Inc. , a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that its lead...

at 07:30
FSD Pharma Inc. ("FSD Pharma" or the "Company") (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the...

at 07:30
According to the latest market report published by Transparency Market Research titled "Sterile Medical Packaging Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2018-2026."      (Logo:...

at 07:27
As Curaleaf celebrates the opening of its 9th dispensary in Florida today, the company is proud to announce same-day or next-day statewide delivery of its premium quality, precise and reliable medical marijuana products, including its newest product...




News published on 2 january 2018 at 12:30 and distributed by: